Clinical trials: Prognostic Biomarkers
Pericarditis
Prognostic Biomarkers in Patients With Acute Pericarditis
The study will aim at investigating novel plasma or imaging biomarkers in patients with acute pericarditis. All participants will be treated according to established clinical recommendations for the diagnosis and treatment of…
- Trial name
- NCT02754713
- Where
- Greece
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Hippocration General Hospital
Metastatic Melanoma, Immune Checkpoints Inhibitors
Biomarkers in Immunotherapy of Melanoma
Background: Immunotherapy has been successful in treating advanced melanoma, but a large proportion of patients do not respond to the treatment with immune checkpoint inhibitors (ICIs).
- Conditions
- Metastatic Melanoma, Immune Checkpoints Inhibitors, Gastrointestinal Microbiome (Bacterial and Viral), Exosomal mRNA Expression of PD-L1 and IFNγ
- Trial name
- NCT05878977
- Testing
- Immune checkpoint inhibitor
- Where
- Slovenia
- Volunteers
- 150 people
- Sponsor
- Institute of Oncology Ljubljana
HIE - Hypoxic - Ischemic Encephalopathy, Language Delay
Speech of Kids After Neonatal Encephalopathy
The goal of this ambispective cohort study is to reveal the early indicators of delayed language development in children born with hypoxic-ischemic encephalopathy (HIE).
- Conditions
- HIE - Hypoxic - Ischemic Encephalopathy, Language Delay, Autism, ADHD - Attention Deficit Disorder With Hyperactivity
- Trial name
- SANE (NCT07136636)
- Where
- Hungary
- Volunteers
- 93 people
- Sponsor
- Semmelweis University
Acute Lymphoblastic Leukemia
Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia
The purpose of the study is to determine the utility of XCL1 in the prognosis of acute lymphoblastic leukemia.
- Trial name
- XCL1 (NCT01380587)
- Where
- Mexico
- Volunteers
- 25 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Pre-eclampsia
Oxford Luteal Dysfunction and Placental Insufficiency Study
High blood pressure (BP) affects approximately 1 in 10 pregnancies. About half of women with high blood pressure in pregnancy develop a serious complication called preeclampsia, which kills over 70,000 women and 500,000 babies…
- Trial name
- OxLuPIn (NCT07072052)
- Testing
- No intervention planned
- Where
- United Kingdom
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Hepatocellular Carcinoma
Analysis of Expression of Specific Markers and Their Prognostic Significance in Hepatocellular Carcinoma
Hepatocellular carcinoma is an aggressive disease with limited therapeutic options. Therefore, new approaches to treat this type of cancer are needed with immunotherapy potentially being one of these.
- Trial name
- NCT00911196
- Testing
- Retrospective analysis of already archived samples
- Where
- 3 sites in Taiwan, Thailand
- Volunteers
- 200 people
- Sponsor
- GlaxoSmithKline
Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer
This phase II trial studies how well pembrolizumab and tamoxifen with or without vorinostat work for the treatment of estrogen receptor positive breast cancer.
- Trial name
- NCT04190056
- Testing
- Pembrolizumab, Tamoxifen, Vorinostat
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of California, San Francisco
Parkinson Disease, Multiple System Atrophy
Diagnostic and Prognostic Biomarkers in Parkinson Disease
The overall goal of PROBE is to evaluate the feasibility and potential utility of three markers (alpha-synuclein, transcriptomic profiles and olfactory function) to determine the risk or prognosis of PD.
- Conditions
- Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- PROBE (NCT00653783)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- The Parkinson Study Group
Multiple Sclerosis, Radiologically Isolated Syndrome
Prognostic Value of Three New Biomarkers of Multiple Sclerosis in Patients With Radiologically Isolated Syndrome
To look at the prognostic value of new biomarkers in CSF and serum for characterisation of multiple sclerosis
- Trial name
- T-RIS (NCT03357887)
- Testing
- Analysis of cerebrospinal fluid and serum
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes